FDA Expands Approval of Fulvestrant for Advanced Breast Cancer

| September 22, 2017 | 0 Comments
FDA Expands Approval of Fulvestrant for Advanced Breast Cancer

FDA has expanded its approval of fulvestrant (Faslodex®) as a standalone treatment for postmenopausal women with advanced HR-positive, HER2-negative breast cancer who have not previously undergone endocrine therapy.
See Original Article

Category: Recent News

About the Author ()

Leave a Reply